The beneficial effects of deferred delivery on the efficiency of hydrogel therapy post myocardial infarction

Biomaterials

Volumn 33, Issue 7, 2012, Pages 2060-2066

  Kadner, Karen ^a   Dobner, Stephan ^a   Franz, Thomas ^a,b   Bezuidenhout, Deon ^a   Sirry, Mazin S ^a   Zilla, Peter ^a   Davies, Neil H ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b CENTRE FOR HIGH PERFORMANCE COMPUTING   (South Africa)

Author keywords

Heart; Hydrogel; Infarction; Remodelling

Indexed keywords

BENEFICIAL EFFECTS; CARDIAC STRUCTURE; DEGRADABILITY; END-SYSTOLIC; INFARCTION; MYOCARDIAL INFARCTION; PEPTIDE SEQUENCES; REMODELLING; SALINE CONTROL; TIME POINTS; VENTRICULAR WALLS;

BIOLOGICAL MATERIALS; GLYCOLS; HEART; MORPHOLOGY; POLYETHYLENE GLYCOLS;

HYDROGELS;

MACROGOL;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART FUNCTION; HEART INFARCTION; HYDROGEL; MALE; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOCOMPATIBLE MATERIALS; DRUG DELIVERY SYSTEMS; HEART; HUMANS; HYDROGELS; MALE; MYOCARDIAL INFARCTION; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; VENTRICULAR REMODELING;

EID: 84855755104     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.11.031     Document Type: Article

References (30)

1. National Institute of Health. National Heart Lung and Blood Institute Factbook Fiscal Year 2008. http://www.nhlbi.nih.gov/about/factbook/FactBookFinal.pdf.
2. McMurray J.J., Pfeffer M.A. Heart failure. Lancet 2005, 365(9474):1877-1889.
3. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121(7):e46-e215.
4. Velagaleti R.S., Pencina M.J., Murabito J.M., Wang T.J., Parikh N.I., D'Agostino R.B., et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 2008, 118(20):2057-2062.
5. Wittwer T., Wahlers T. Marginal donor grafts in heart transplantation: lessons learned from 25 years of experience. Transpl Int 2008, 21(2):113-125.
6. Sutton M.G., Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000, 101(25):2981-2988.
7. Holmes J.W., Borg T.K., Covell J.W. Structure and mechanics of healing myocardial infarcts. Annu Rev Biomed Eng 2005, 7:223-253.
8. Opie L.H., Commerford P.J., Gersh B.J., Pfeffer M.A. Controversies in ventricular remodelling. Lancet 2006, 367(9507):356-367.
9. Kober L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., et al. Aclinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) study group. NEngl J Med 1995, 333(25):1670-1676.
10. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. NEngl J Med 1992, 327(10):669-677.
11. Nelson D.M., Ma Z., Fujimoto K.L., Hashizume R., Wagner W.R. Intra-myocardial biomaterial injection therapy in the treatment of heart failure: materials, outcomes and challenges. Acta Biomater 2011, 7(1):1-15.
12. Christman K.L., Fok H.H., Sievers R.E., Fang Q., Lee R.J. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng 2004, 10(3-4):403-409.
13. Christman K.L., Vardanian A.J., Fang Q., Sievers R.E., Fok H.H., Lee R.J. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. JAm Coll Cardiol 2004, 44(3):654-660.
14. Wall S.T., Walker J.C., Healy K.E., Ratcliffe M.B., Guccione J.M. Theoretical impact of the injection of material into the myocardium: a finite element model simulation. Circulation 2006, 114(24):2627-2635.
15. Wenk J.F., Wall S.T., Peterson R.C., Helgerson S.L., Sabbah H.N., Burger M., et al. Amethod for automatically optimizing medical devices for treating heart failure: designing polymeric injection patterns. JBiomech Eng 2009, 131(12):121011.
16. Dai W., Wold L.E., Dow J.S., Kloner R.A. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. JAm Coll Cardiol 2005, 46(4):714-719.
17. Landa N., Miller L., Feinberg M.S., Holbova R., Shachar M., Freeman I., et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 2008, 117(11):1388-1396.
18. Dobner S., Bezuidenhout D., Govender P., Zilla P., Davies N. Asynthetic non-degradable polyethylene glycol hydrogel retards adverse post-infarct left ventricular remodeling. JCard Fail 2009, 15(7):629-636.
19. Fujimoto K.L., Ma Z., Nelson D.M., Hashizume R., Guan J., Tobita K., et al. Synthesis, characterization and therapeutic efficacy of a biodegradable, thermoresponsive hydrogel designed for application in chronic infarcted myocardium. Biomaterials 2009, 30(26):4357-4368.
20. Kofidis T., Lebl D.R., Martinez E.C., Hoyt G., Tanaka M., Robbins R.C. Novel injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue restoration on the beating heart after myocardial injury. Circulation 2005, 112(9 Suppl):I173-I177.
21. Lutolf M.P., Hubbell J.A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 2005, 23(1):47-55.
22. Zisch A.H., Lutolf M.P., Hubbell J.A. Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc Pathol 2003, 12(6):295-310.
23. Takagawa J., Zhang Y., Wong M.L., Sievers R.E., Kapasi N.K., Wang Y., et al. Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches. JAppl Physiol 2007, 102(6):2104-2111.
24. Frangogiannis N.G. The mechanistic basis of infarct healing. Antioxid Redox Signal 2006, 8(11-12):1907-1939.
25. Sanborn T.J., Messersmith P.B., Barron A.E. In situ crosslinking of a biomimetic peptide-PEG hydrogel via thermally triggered activation of factor XIII. Biomaterials 2002, 23(13):2703-2710.
26. Anderson J.M., Rodriguez A., Chang D.T. Foreign body reaction to biomaterials. Semin Immunol 2008, 20(2):86-100.
27. Ifkovits J.L., Tous E., Minakawa M., Morita M., Robb J.D., Koomalsingh K.J., et al. Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model. Proc Natl Acad Sci USA 2010, 107(25):11507-11512.
28. Wang T., Wu D.Q., Jiang X.J., Zhang X.Z., Li X.Y., Zhang J.F., et al. Novel thermosensitive hydrogel injection inhibits post-infarct ventricle remodelling. Eur J Heart Fail 2009, 11(1):14-19.
29. Jiang X.J., Wang T., Li X.Y., Wu D.Q., Zheng Z.B., Zhang J.F., et al. Injection of a novel synthetic hydrogel preserves left ventricle function after myocardial infarction. JBiomed Mater Res A 2009, 90(2):472-477.
30. Menasche P. Cardiac cell therapy: lessons from clinical trials. JMol Cell Cardiol 2011, 50(2):258-265.